News
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes.
Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes. This double-blind, randomized, placebo-controlled, multiple dose Phase II study will evaluate the ability of orally administered CPL’280 to control blood glucose in patients with diagnosed type 2 diabetes. Both naiveRead more »
Celon Pharma at EASD 2021
The EASD Annual Meeting is one of the largest scientific congresses, presenting the latest results from basic and clinical diabetes research and the place to meet the global diabetes community.
Current report 25/2021– Notice on convening the Ordinary General Meeting of Celon Pharma S.A. on June 29, 2021 with draft resolutions
Date prepared: 06/02/2021 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Notice on convening the Ordinary General Meeting of Celon Pharma S.A. on June 29, 2021 with draft resolutions Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: Read more »
Current report 24/2021– The Management Board’s recommendation on the distribution of profit for the year 2020
The Management Board’s recommendation on the distribution of profit for the year 2020
Dynamic export and continuation of positive trends in the development of innovative products
Dynamic export and continuation of positive trends in the development of innovative products
Current report No. 23/2021 – changing dates for submitting periodical reports for the 1st quarter of 2021
Current reports May 17, 2021 Date prepared: May 17,2021 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. informs that the date of releasing the periodical report for 1Q2021 to the public was changed.Read more »
Current report No. 22/2021 – Adoption of a resolution on the issue of shares as part of increasing the Company’s authorized share capital; repealing of the previous resolution
Current reports May 10, 2021 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: Management Board of Celon Pharma S.A. (“Company”) informs that on May 10, 2021 a resolution was adopted concerning the issue of not less than 1 and notRead more »
Current report 21/2021 – entering the authorized capital and the increase in the Company’s share capital into the National Court Register (KRS)
Current reports May 6, 2021 Management Board of Celon Pharma S.A. The “Company” informs that on May 5, 2021, it was entered into the register of the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of the National Court Register, entry in Section No. 8 of the KRS: Adoption ofRead more »
Current report 20/2021– Registration of amendments to the Company’s Articles of Association
Current reports April, 12 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Management Board of Celon Pharma S.A. (The “Company”, “Issuer”) informs that on April 12, 2021 the Regional Court for the capital city of Warsaw in Warsaw, 14th Economic Division of theRead more »
Current report No. 19/2021 – The Company’s financial statements for 2020 prepared in accordance with IFRS, together with comparative data for 2019 and 2018
April, 7 2021 Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Time: 8:45 PM In connection with the approval dated today of the financial statements of Celon Pharma S.A. (the “Company”) prepared in accordance with International Financial Reporting Standards (“IFRS”), covering the year which ended on December 31,Read more »